Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
26 Jan 2024
Historique:
received: 13 04 2023
accepted: 12 01 2024
medline: 27 1 2024
pubmed: 27 1 2024
entrez: 26 1 2024
Statut: epublish

Résumé

There is still incomplete knowledge of which Mycobacterium tuberculosis (Mtb) antigens can trigger distinct T cell responses at different stages of infection. Here, a proteome-wide screen of 20,610 Mtb-derived peptides in 21 patients mid-treatment for active tuberculosis (ATB) reveals IFNγ-specific T cell responses against 137 unique epitopes. Of these, 16% are recognized by two or more participants and predominantly derived from cell wall and cell processes antigens. There is differential recognition of antigens, including TB vaccine candidate antigens, between ATB participants and interferon-gamma release assay (IGRA + /-) individuals. We developed an ATB-specific peptide pool (ATB116) consisting of epitopes exclusively recognized by ATB participants. This pool can distinguish patients with pulmonary ATB from IGRA + /- individuals from various geographical locations, with a sensitivity of over 60% and a specificity exceeding 80%. This proteome-wide screen of T cell reactivity identified infection stage-specific epitopes and antigens for potential use in diagnostics and measuring Mtb-specific immune responses.

Identifiants

pubmed: 38278794
doi: 10.1038/s41467-024-45058-9
pii: 10.1038/s41467-024-45058-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

765

Subventions

Organisme : NIAID NIH HHS
ID : 75N93019C00067
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI137681
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00067
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272200900044C
Pays : United States

Informations de copyright

© 2024. The Author(s).

Références

Global tuberculosis report 2021 [Internet]. [cited Mar 30]. Available from: https://www.who.int/publications-detail-redirect/9789240037021 (2023).
Barry, C. E. et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845–855 (2009).
pubmed: 19855401 pmcid: 4144869 doi: 10.1038/nrmicro2236
Lewinsohn, D. M. & Lewinsohn, D. A. New Concepts in Tuberculosis Host Defense. Clin. Chest Med. 40, 703–719 (2019).
pubmed: 31731979 doi: 10.1016/j.ccm.2019.07.002
Pai, M. et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin. Microbiol Rev. 27, 3–20 (2014).
pubmed: 24396134 pmcid: 3910908 doi: 10.1128/CMR.00034-13
Yang, H., Kruh-Garcia, N. A. & Dobos, K. M. Purified protein derivatives of tuberculin — past, present, and future. FEMS Immunol. Med Microbiol. 66, 273–280 (2012).
pubmed: 22762692 pmcid: 3491170 doi: 10.1111/j.1574-695X.2012.01002.x
Huebner, R. E., Schein, M. F. & Bass, J. B. The tuberculin skin test. Clin. Infect. Dis. Publ. Infect. Dis. Soc. Am. 17, 968–975 (1993).
doi: 10.1093/clinids/17.6.968
Farhat, M., Greenaway, C., Pai, M. & Menzies, D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J. Tuberc. Lung Dis. J. Int Union Tuberc. Lung Dis. 10, 1192–1204 (2006).
Hill, P. C. et al. ESAT-6/CFP-10 fusion protein and peptides for optimal diagnosis of mycobacterium tuberculosis infection by ex vivo enzyme-linked immunospot assay in the Gambia. J. Clin. Microbiol. 43, 2070–2074 (2005).
pubmed: 15872224 pmcid: 1153808 doi: 10.1128/JCM.43.5.2070-2074.2005
Chegou, N. N., Black, G. F., Kidd, M., van Helden, P. D. & Walzl, G. Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm. Med. 9, 21 (2009).
pubmed: 19445695 pmcid: 2696407 doi: 10.1186/1471-2466-9-21
Lin, P. L. & Flynn, J. L. CD8 T cells and Mycobacterium tuberculosis infection. Semin Immunopathol. 37, 239–249 (2015).
pubmed: 25917388 pmcid: 4439333 doi: 10.1007/s00281-015-0490-8
Mayer-Barber, K. D. & Barber, D. L. Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. Cold Spring Harb. Perspect. Med. 5, a018424 (2015).
pubmed: 26187873 pmcid: 4665043 doi: 10.1101/cshperspect.a018424
Boom, W. H. Gammadelta T cells and Mycobacterium tuberculosis. Microbes Infect. 1, 187–195 (1999).
pubmed: 10801229 doi: 10.1016/S1286-4579(99)80033-1
Huang, S. Targeting Innate-Like T Cells in Tuberculosis. Front Immunol. 7, 594 (2016).
pubmed: 28066410 pmcid: 5175204 doi: 10.3389/fimmu.2016.00594
Van Rhijn, I. & Moody, D. B. Donor Unrestricted T Cells: A Shared Human T Cell Response. J. Immunol. Balt. Md 1950. 195, 1927–1932 (2015).
Morgan, J. et al. Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Immunol. Rev. 301, 10–29 (2021).
pubmed: 33751597 pmcid: 8252593 doi: 10.1111/imr.12963
Havlir, D. V. & Barnes, P. F. Tuberculosis in Patients with Human Immunodeficiency Virus Infection. N. Engl. J. Med. 340, 367–373 (1999).
pubmed: 9929528 doi: 10.1056/NEJM199902043400507
Arlehamn, C. S. L. et al. Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7.7), and Rv1038c (EsxJ). J. Immunol. Balt. Md 1950. 188, 5020–5031 (2012).
Vordermeier, M., Whelan, A. O. & Hewinson, R. G. Recognition of Mycobacterial Epitopes by T Cells across Mammalian Species and Use of a Program That Predicts Human HLA-DR Binding Peptides To Predict Bovine Epitopes. Infect. Immun. 71, 1980–1987 (2003).
pubmed: 12654816 pmcid: 152066 doi: 10.1128/IAI.71.4.1980-1987.2003
Hammond, A. S. et al. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8+ T cell epitopes. Clin. Exp. Immunol. 140, 109–116 (2005).
pubmed: 15762882 pmcid: 1809330 doi: 10.1111/j.1365-2249.2005.02751.x
McMurry, J. et al. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis 85, 95–105 (2005).
pubmed: 15687033 doi: 10.1016/j.tube.2004.09.005
Lindestam Arlehamn, C. S., Lewinsohn, D., Sette, A. & Lewinsohn, D. Antigens for CD4 and CD8 T cells in tuberculosis. Cold Spring Harb. Perspect. Med. 4, a018465 (2014).
pubmed: 24852051 pmcid: 4066646 doi: 10.1101/cshperspect.a018465
Lindestam Arlehamn, C. S. et al. Memory T cells in latent Mycobacterium tuberculosis infection are directed against three antigenic islands and largely contained in a CXCR3+CCR6+ Th1 subset. PLoS Pathog. 9, e1003130 (2013).
pubmed: 23358848 pmcid: 3554618 doi: 10.1371/journal.ppat.1003130
Weiskopf, D. et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc. Natl Acad. Sci. Usa. 110, E2046–E2053 (2013).
pubmed: 23580623 pmcid: 3670335 doi: 10.1073/pnas.1305227110
Hinz, D. et al. Definition of a pool of epitopes that recapitulates the T cell reactivity against major house dust mite allergens. Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 45, 1601–1612 (2015).
doi: 10.1111/cea.12507
Schulten, V. et al. Previously undescribed grass pollen antigens are the major inducers of T helper 2 cytokine-producing T cells in allergic individuals. Proc. Natl Acad. Sci. Usa. 110, 3459–3464 (2013).
pubmed: 23401558 pmcid: 3587276 doi: 10.1073/pnas.1300512110
Commandeur, S. et al. An Unbiased Genome-Wide Mycobacterium tuberculosis Gene Expression Approach To Discover Antigens Targeted by Human T Cells Expressed during Pulmonary Infection. J. Immunol. 190, 1659–1671 (2013).
pubmed: 23319735 doi: 10.4049/jimmunol.1201593
Coppola, M. et al. In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. NPJ Vaccines. 6, 81 (2021).
pubmed: 34083546 pmcid: 8175414 doi: 10.1038/s41541-021-00343-2
Aagaard, C. S., Hoang, T. T., Vingsbo-Lundberg, C., Dietrich, J. & Andersen, P. Quality and vaccine efficacy of CD4+ T cell responses directed to dominant and subdominant epitopes in ESAT-6 from Mycobacterium tuberculosis. J. Immunol. Balt. Md. 183, 2659–2668 (2009).
Lindestam Arlehamn C., Sette A. Definition of CD4 Immunosignatures Associated with MTB. Front Immunol [Internet]. [cited 2023 Mar 31];5. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2014.00124 (2014).
Wambre, E. et al. Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. J. Allergy Clin. Immunol. 133, 872–879.e7 (2014).
pubmed: 24373351 doi: 10.1016/j.jaci.2013.10.054
Grifoni, A. et al. Defining antigen targets to dissect vaccinia virus and monkeypox virus-specific T cell responses in humans. Cell Host Microbe 30, 1662–1670.e4 (2022).
pubmed: 36463861 pmcid: 9718645 doi: 10.1016/j.chom.2022.11.003
Tarke, A. et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep. Med. 2, 100204 (2021).
pubmed: 33521695 pmcid: 7837622 doi: 10.1016/j.xcrm.2021.100204
Arif, S., Akhter, M., Khaliq, A. & Akhtar, M. W. Fusion peptide constructs from antigens of M. tuberculosis producing high T-cell mediated immune response. PloS One 17, e0271126 (2022).
pubmed: 36174012 pmcid: 9521936 doi: 10.1371/journal.pone.0271126
Wang, X. et al. Identification and evaluation of the novel immunodominant antigen Rv2351c from Mycobacterium tuberculosis. Emerg. Microbes Infect. 6, 1–8 (2017).
Desvignes, L., Wolf, A. J. & Ernst, J. D. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J. Immunol. Balt. Md 1950. 188, 6205–6215 (2012).
Petruccioli, E. et al. Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. Eur. Respir. J. 48, 1751–1763 (2016).
pubmed: 27836953 pmcid: 5898936 doi: 10.1183/13993003.01012-2016
Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249–2254 (1993).
pubmed: 7504064 doi: 10.1084/jem.178.6.2249
Kumar, P. I. F. N. γ-producing CD4+ T lymphocytes: the double-edged swords in tuberculosis. Clin. Transl. Med. 6, 21 (2017).
pubmed: 28646367 pmcid: 5482791 doi: 10.1186/s40169-017-0151-8
Rai, P. K. et al. A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host. Sci. Rep. 6, 23917 (2016).
pubmed: 27052185 pmcid: 4823727 doi: 10.1038/srep23917
Ruhwald, M. et al. Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6. Sci. Rep. 7, 45969 (2017).
pubmed: 28387329 pmcid: 5384086 doi: 10.1038/srep45969
Lew, J. M., Kapopoulou, A., Jones, L. M. & Cole, S. T. TubercuList–10 years after. Tuberc. Edinb. Scotl. 91, 1–7 (2011).
Arlehamn, C. S. L. et al. A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLOS Pathog. 12, e1005760 (2016).
doi: 10.1371/journal.ppat.1005760
Oseroff, C. et al. Molecular determinants of T cell epitope recognition to the common Timothy grass allergen. J. Immunol. Balt. Md. 185, 943–955 (2010).
Lindestam Arlehamn, C. S. et al. Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes. Proc. Natl Acad. Sci. 112, E147–E155 (2015).
pubmed: 25548174 doi: 10.1073/pnas.1416537112
Bettencourt, P. et al. Identification of antigens presented by MHC for vaccines against tuberculosis. NPJ Vaccines. 5, 2 (2020).
pubmed: 31908851 pmcid: 6941960 doi: 10.1038/s41541-019-0148-y
Wang, Y. et al. Systematic Evaluation of Mycobacterium tuberculosis Proteins for Antigenic Properties Identifies Rv1485 and Rv1705c as Potential Protective Subunit Vaccine Candidates. Infect. Immun. 89, e00585–20 (2021).
pubmed: 33318140 pmcid: 8097267 doi: 10.1128/IAI.00585-20
Lewinsohn, D. M. et al. Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library. PloS One 8, e67016 (2013).
pubmed: 23805289 pmcid: 3689843 doi: 10.1371/journal.pone.0067016
Meier, N. R., Jacobsen, M., Ottenhoff, T. H. M. & Ritz, N. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Front Immunol. 9, 2476 (2018).
pubmed: 30473692 pmcid: 6237970 doi: 10.3389/fimmu.2018.02476
Woodworth, J. S. et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin. Nat. Commun. 12, 1–13 (2021).
doi: 10.1038/s41467-021-26934-0
Rodo, M. J. et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog. 15, e1007643 (2019).
pubmed: 30830940 pmcid: 6417742 doi: 10.1371/journal.ppat.1007643
Stylianou, E. et al. Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine. Infect. Immun. 86, e00014–e00018 (2018).
pubmed: 29661928 pmcid: 6013653 doi: 10.1128/IAI.00014-18
Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N. Engl. J. Med. 379, 138–149 (2018).
pubmed: 29996082 pmcid: 5937161 doi: 10.1056/NEJMoa1714021
Tait, D. R. et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N. Engl. J. Med. 381, 2429–2439 (2019).
pubmed: 31661198 doi: 10.1056/NEJMoa1909953
Scriba, T. J. et al. Differential Recognition of Mycobacterium tuberculosis–Specific Epitopes as a Function of Tuberculosis Disease History. Am. J. Respir. Crit. Care Med. 196, 772–781 (2017).
pubmed: 28759253 pmcid: 5620682 doi: 10.1164/rccm.201706-1208OC
Schnappinger, D. et al. Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J. Exp. Med. 198, 693–704 (2003).
pubmed: 12953091 pmcid: 2194186 doi: 10.1084/jem.20030846
Moguche, A. O. et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe 21, 695–706.e5 (2017).
pubmed: 28618268 pmcid: 5533182 doi: 10.1016/j.chom.2017.05.012
Day, C. L. et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J. Immunol. Balt. Md. 187, 2222–2232 (2011).
Harari, A. et al. Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat. Med. 17, 372–376 (2011).
pubmed: 21336285 pmcid: 6570988 doi: 10.1038/nm.2299
Hutchinson, P. et al. Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection. Clin. Vaccin. Immunol. Cvi. 22, 200–212 (2015).
pubmed: 25520147 doi: 10.1128/CVI.00607-14
Caccamo, N. et al. Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol. 40, 2211–2220 (2010).
pubmed: 20540114 doi: 10.1002/eji.201040455
Sutherland, J. S., Adetifa, I. M., Hill, P. C., Adegbola, R. A. & Ota, M. O. C. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur. J. Immunol. 39, 723–729 (2009).
pubmed: 19224636 doi: 10.1002/eji.200838693
Burel, J. G. et al. Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. Tuberc. Edinb. Scotl. 131, 102127 (2021).
Andersen, P. & Scriba, T. J. Moving tuberculosis vaccines from theory to practice. Nat. Rev. Immunol. 19, 550–562 (2019).
pubmed: 31114037 doi: 10.1038/s41577-019-0174-z
Arrigucci R., et al. Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells. Front Immunol [Internet]. [cited 2023 Mar 31];9. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2018.02127 (2018)
Petruccioli, E. et al. IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosis. J. Infect. 66, 475–486 (2013).
pubmed: 23462597 doi: 10.1016/j.jinf.2013.02.004
El Fenniri, L. et al. Polyfunctional Mycobacterium tuberculosis-specific effector memory CD4+ T cells at sites of pleural TB. Tuberc. Edinb. Scotl. 91, 224–230 (2011).
Pollock, K. M. et al. T-cell immunophenotyping distinguishes active from latent tuberculosis. J. Infect. Dis. 208, 952–968 (2013).
pubmed: 23966657 pmcid: 3749005 doi: 10.1093/infdis/jit265
Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who’s who of T-cell differentiation: Human memory T-cell subsets. Eur. J. Immunol. 43, 2797–2809 (2013).
pubmed: 24258910 doi: 10.1002/eji.201343751
Strickland, N. et al. Characterization of Mycobacterium tuberculosis-Specific Cells Using MHC Class II Tetramers Reveals Phenotypic Differences Related to HIV Infection and Tuberculosis Disease. J. Immunol. Balt. Md 1950. 9, ji1700849 (2017).
Acosta-Rodriguez, E. V. et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8, 639–646 (2007).
pubmed: 17486092 doi: 10.1038/ni1467

Auteurs

Sudhasini Panda (S)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.

Jeffrey Morgan (J)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.

Catherine Cheng (C)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.

Mayuko Saito (M)

Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Robert H Gilman (RH)

Johns Hopkins School of Public Health, Baltimore, MD, USA.
Universidad Peruana Cayetano Heredia, Lima, Peru.

Nelly Ciobanu (N)

Phthisiopneumology Institute, Chisinau, Republic of Moldova.

Valeriu Crudu (V)

Phthisiopneumology Institute, Chisinau, Republic of Moldova.

Donald G Catanzaro (DG)

Department of Biological Sciences, University of Arkansas, Fayetteville, AR, USA.

Antonino Catanzaro (A)

Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Timothy Rodwell (T)

Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Judy S B Perera (JSB)

Faculty of Medicine, General Sir John Kotelawala Defense University, Ratmalana, Sri Lanka.

Teshan Chathuranga (T)

Faculty of Medicine, General Sir John Kotelawala Defense University, Ratmalana, Sri Lanka.

Bandu Gunasena (B)

National Hospital for Respiratory Diseases, Welisara, Sri Lanka.

Aruna D DeSilva (AD)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Faculty of Medicine, General Sir John Kotelawala Defense University, Ratmalana, Sri Lanka.

Bjoern Peters (B)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Alessandro Sette (A)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA.
Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Cecilia S Lindestam Arlehamn (CS)

Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA. cecilia@lji.org.

Classifications MeSH